Breaks Categories: News

ThursdayJul 15, 2021 2:52 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Premieres New Clubhouse Show Titled ‘Activate Your Superhuman Mind’

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, announced that its new weekly talk show is scheduled to premiere on Clubhouse, a new type of social network based on voice. The increasingly popular channel enables millions of people around the world to gather to talk, listen and learn from each other in real time. The talk show, titled “Activate Your Superhuman Mind,” will cover a range of topics focused on achieving superior mental focus and energy. A new episode will be broadcast every Thursday, from 7:30–8:30 p.m. ET. The most recent episode, called…

Continue Reading

ThursdayJul 15, 2021 12:58 pm

BioMedNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The…

Continue Reading

TuesdayJul 13, 2021 11:48 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of the 74 adult patients treated with the company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, defined as patients having an Apnea Hypopnea Index (“AHI”) score of less than five post-treatment. “We are not aware of any treatment for…

Continue Reading

MondayJul 12, 2021 10:27 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening…

Continue Reading

FridayJul 09, 2021 10:18 am

BioMedNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in a panel discussion titled “Updates in Neuropsych.” Key executives will also be available for one-on-one meetings throughout the virtual conference, which will be held July 15. The panel discussion is slated to begin at 9 a.m. PT. In the announcement, VTGN noted that the panel…

Continue Reading

ThursdayJul 08, 2021 12:47 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Announces Ultimate Brain Nutrients ACTIVATE, a Breakthrough Nutraceutical Formulation

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain health, has unveiled a game-changing nutraceutical formulation: Ultimate Brain Nutrients ACTIVATE(TM) (“UBN”). According to the company, clinical studies indicate that the proprietary formulation naturally increases key brain activity by as much as 46%. Other results from studies show that ACTIVATE significantly improves human cognitive behavior and mental focus by activating areas of the brain that are key in attention, memory, mood and quick reaction times. HYEX has devoted more than two decades in research on the formulation, which included approximately 100 clinical studies…

Continue Reading

WednesdayJul 07, 2021 1:48 pm

BioMedNewsBreaks – Numinus Wellness Inc. (TSX.V: NUMI) Announces Plans to Combine Expertise, Create Centre for Excellence in Psychedelic Neurology

Numinus Wellness (TSX.V: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has agreed to acquire the Neurology Centre of Toronto ("NCT") pursuant to a purchase agreement dated July 2, 2021. According to the update, Numinus and NCT founder Dr. Evan Lewis plan to expand NCT into a comprehensive clinical neurology treatment centre with a unique specialization in the application of psychedelics in the field of neurology. “This acquisition represents an exciting opportunity for NCT and Numinus to combine medical, clinical and academic expertise to help create a new discipline and…

Continue Reading

WednesdayJul 07, 2021 1:40 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that 63% of patients reported that they depend on their dentist’s advice as they look for lasting solutions that addresses the root cause of their OSA and 29% indicated they searched for nonsurgical alternatives to current…

Continue Reading

WednesdayJul 07, 2021 1:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the future of mental health and wellness,” said VistaGen CEO Shawn Singh.…

Continue Reading

WednesdayJul 07, 2021 10:07 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio for the company's novel TRP-8803 drug formulation compared with conventional oral formulations of synthetic psilocybin. The studies will also facilitate the advancement of TRP-8803 into Phase 2b clinical trials. “We are excited to initiate our…

Continue Reading